Data shows booster Covid shots 'not appropriate' for public: Lancet

Vaccine efficacy against severe Covid-19 is so high, even for the Delta variant, that booster doses for the general population are "not appropriate" at this stage in the pandemic, a Lancet report said

vaccination
Photo: Bloomberg
IANS New York
3 min read Last Updated : Sep 14 2021 | 1:09 PM IST

Vaccine efficacy against severe Covid-19 is so high, even for the Delta variant, that booster doses for the general population are "not appropriate" at this stage in the pandemic, an international group of scientists argued in a review published in The Lancet.

The review, which includes scientists from the World Health Organization (WHO) and two from the US Food and Drug Administration (FDA), who will leave the agency, comes even as the latter is currently reviewing evidence for booster doses for Americans; and many other countries including Israel, Italy, France and Russia who have already rolled out the third dose of Covid jabs.

It summarises the currently available evidence from randomised controlled trials and observational studies published in peer-reviewed journals and pre-print servers and asserts that the benefits of the first shots are clear.

It added that vaccination had 95 per cent efficacy against severe disease both from the Delta variant and from the Alpha variant, and over 80 per cent efficacy at protecting against any infection from these variants.

Although vaccines are less effective against asymptomatic disease or against transmission than against severe disease, the unvaccinated minority are still the major drivers of transmission, the scientists argued in the review published on Monday.

"Taken as a whole, the currently available studies do not provide credible evidence of substantially declining protection against severe disease, which is the primary goal of vaccination. Even if some gain can ultimately be obtained from boosting, it will not outweigh the benefits of providing initial protection to the unvaccinated," said lead author Ana-Maria Henao-Restrepo from the WHO.

Last week, Pascal Soriot, CEO of AstraZeneca, also said that a third dose of vaccines against Covid-19 may not be needed for everyone.

Writing in the Telegraph, he stated that the decision to jab the entire population must be based on "real world clinical effectiveness data, not simply antibody measurements".

The WHO has, meanwhile, called for an extension of a global moratorium on Covid-19 booster doses, with an aim to enable every country to vaccinate at least 40 per cent of its population.

According to the WHO, globally 5.5 billion vaccine doses have been administered, but 80 per cent have been administered in high- and upper-middle income countries.

WHO Director-General Tedros Adhanom Ghebreyesus reiterated that third doses may be necessary for the most at-risk populations, but for now, "we do not want to see widespread use of boosters for healthy people who are fully vaccinated".

"The vaccines that are currently available are safe, effective, and save lives. Although the idea of further reducing the number of Covid-19 cases by enhancing immunity in vaccinated people is appealing, any decision to do so should be evidence-based and consider the benefits and risks for individuals and society.

"These high-stakes decisions should be based on robust evidence and international scientific discussion," adds co-author Soumya Swaminathan, WHO Chief Scientist.

--IANS

rvt/ksk/

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineLancet reportVaccination

First Published: Sep 14 2021 | 1:09 PM IST

Next Story